Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) kicked off on Tuesday, down -3.94% from the previous trading day, before settling in for the closing price of $20.28. Over the past 52 weeks, KNSA has traded in a range of $16.56-$28.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 110.12% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 212.29%. With a float of $40.15 million, this company’s outstanding shares have now reached $41.88 million.
In an organization with 315 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.54%, operating margin of -10.78%, and the pretax margin is -8.54%.
Kiniksa Pharmaceuticals International Plc (KNSA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Kiniksa Pharmaceuticals International Plc is 44.73%, while institutional ownership is 56.59%. The most recent insider transaction that took place on Mar 20 ’25, was worth 368,466. In this transaction CHIEF FINANCIAL OFFICER of this company sold 15,944 shares at a rate of $23.11, taking the stock ownership to the 23,382 shares. Before that another transaction happened on Mar 17 ’25, when Company’s CHIEF FINANCIAL OFFICER sold 11,464 for $23.10, making the entire transaction worth $264,818. This insider now owns 23,382 shares in total.
Kiniksa Pharmaceuticals International Plc (KNSA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 212.29% per share during the next fiscal year.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Trading Performance Indicators
Take a look at Kiniksa Pharmaceuticals International Plc’s (KNSA) current performance indicators. Last quarter, stock had a quick ratio of 3.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.34. Likewise, its price to free cash flow for the trailing twelve months is 55.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit 0.14 in the next quarter and is forecasted to reach 1.24 in one year’s time.
Technical Analysis of Kiniksa Pharmaceuticals International Plc (KNSA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.65 million. That was better than the volume of 0.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 14.80%. Additionally, its Average True Range was 1.02.
During the past 100 days, Kiniksa Pharmaceuticals International Plc’s (KNSA) raw stochastic average was set at 25.58%, which indicates a significant increase from 4.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.43% in the past 14 days, which was higher than the 37.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.98, while its 200-day Moving Average is $22.46. However, in the short run, Kiniksa Pharmaceuticals International Plc’s stock first resistance to watch stands at $20.76. Second resistance stands at $22.03. The third major resistance level sits at $22.76. If the price goes on to break the first support level at $18.76, it is likely to go to the next support level at $18.03. The third support level lies at $16.76 if the price breaches the second support level.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Key Stats
The company with the Market Capitalisation of 1.42 billion has total of 72,644K Shares Outstanding. Its annual sales at the moment are 423,240 K in contrast with the sum of -43,190 K annual income. Company’s last quarter sales were recorded 122,540 K and last quarter income was -8,890 K.
